Sign up to receive our twice-weekly e-Newsletter
NNRTI IDX899
Experimental NNRTI IDX899
Exhibits Good Antiviral Activity in 7-day Phase I/II Clinical Trial
9/12/2008
New NNRTIs
IDX899 and RDE806
Appear Safe and Effective in Early Clinical Trials
8/15/2008
Idenix Reports Promising Results from Clinical Trial of
Experimental NNRTI IDX899
6/26/2008
FDA-approved HIV
and AIDS Treatments
Protease Inhibitors
PIs
non Nucleoside Reverse
Transcriptase Inhibitors
nNRTIs
Nucleoside / Nucleotide
Reverse Transcriptase Inhibitors
NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors
EIs
Integrase Inhibitors
Experimental Treatments
HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children
